정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 681 | Withdrawn | Safety and Efficacy of Baricitinib for COVID-19 | COVID-19 | Drug: Baricitinib | Phase 3 | University of Colorado, Denver | OTHER | 0 | All | 18 Years ~ 89 Years | University of Colorado, Denver, Aurora, Colorado, United States |
| 680 | Completed | Safety and Efficacy of C21 in Subjects With COVID-19 | COVID-19 | Drug: C21 Drug: Placebo |
Phase 2 | Vicore Pharma AB, Orphan Reach | INDUSTRY | 206 | All | 18 Years ~ 70 Years | Department of Medicine, Civil Hospital and B J Medical College, Ahmadabad, Gujarat, India Infectious Disease, Metas Adventist Hospital, Surat, Gujarat, India Clinical Research Department, Basement, Unity Trauma Centre and ICU (Unity Hospital, Surat, Gujarat, India First Floor Clinical Research Department Rhythm Heart Institute, Vadodara, Gujarat, India Internal Medicine S.L. Raheja Hospital, Mumbai, Maharashtra, India Department of Medicine, Government Medical College and Hospital, Nagpur, Maharashtra, India Neuro Critical Care, Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India Department of Medicine, Noble Hospitals Pvt. Ltd, Pune, Maharashtra, India Respiratory Medicine, University College Hospital, London, United Kingdom |
| 679 | Recruiting | Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS | Acute Lung Injury | Biological: CAStem | Phase 2 | Chinese Academy of Sciences, Beijing YouAn Hospital | OTHER_GOV | 9 | All | 18 Years ~ 70 Years | Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China, China |
| 678 | Recruiting | Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19 | COVID-19 | Biological: convalescent plasma | Phase 3 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Hospital San Jose Tec de Monterrey, Instituto Nacional de Enfermedades Respiratorias, Instituto Nacional de Cardiologia Ignacio Chavez, Hospital General Dr. Manuel Gea Gonzalez, Hospital Regional de Alta Especialidad del Bajio, Instituto Nacional de Cancerologia de Mexico | OTHER | 410 | All | 18 Years | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Tlalpan, Mexico |
| 677 | Recruiting | Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome | Cytokine Release Syndrome | Drug: dapansutrile capsules Drug: placebo capsules |
Phase 2 | Olatec Therapeutics LLC, CTI Clinical Trial and Consulting Services | INDUSTRY | 80 | All | 18 Years | National Jewish Health, Denver, Colorado, United States C&R Research Services USA, Coral Gables, Florida, United States Invesclinic U.S. LLC, Fort Lauderdale, Florida, United States Sunrise Research Institute, Sunrise, Florida, United States DBC Research Corp, Tamarac, Florida, United States Atrium Health/Charlotte-Mecklenburg Hospital Authority, Charlotte, North Carolina, United States PanAmerican Clinical Research LLC, Brownsville, Texas, United States J & S Studies, Inc., College Station, Texas, United States C&R Research Services USA, Houston, Texas, United States Texas Research Alliance LLC, McAllen, Texas, United States VieCuri Medisch Centrum, Venlo, Netherlands University Hospital Basel, Basel, Switzerland |
| 676 | Recruiting | Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19 | COVID-19 | Drug: Doxycycline Tablets Drug: Rivaroxaban 15Mg Tab Combination Product: Hydroxychloroquine and Azithromycin |
Phase 4 | Yaounde Central Hospital | OTHER_GOV | 200 | All | 18 Years | Yaounde Central Hospital, Yaounde, Centre, Cameroon |
| 675 | Recruiting | Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients | Covid19 | Biological: Dupilumab Drug: Placebo |
Phase 2 | University of Virginia, PBM C19 Research, LLC (a COVID-19 research entity of the Paul Manning Foundation), Virginia Catalyst, Virginia Biosciences Health Research Corporation (VBHRC) | OTHER | 40 | All | 18 Years | UVA Health, Charlottesville, Virginia, United States |